Drug intelligence / Profile preview

CS10BR05

Development stage: Phase 1
Lead developer: Corestemchemon
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial

Overview

CS10BR05 is an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Corestemchemon for the treatment of Multiple System Atrophy (MSA). The therapy involves the isolation and expansion of MSCs from the patient's own bone marrow, which are then administered via intra-arterial injection into the carotid artery. CS10BR05 is designed to exert neuroprotective effects and modulate neuroinflammation, potentially slowing the neurodegenerative process in MSA. It has been evaluated in Phase 1 clinical trials for safety and tolerability, with long-term follow-up studies monitoring efficacy and adverse events.

Other names: autologous bone marrow-derived mesenchymal stem cells

Beyond the preview

Go deeper on CS10BR05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS10BR05.

Explore the full profile